<DOC>
	<DOCNO>NCT00498108</DOCNO>
	<brief_summary>This multicenter , open-label trial ass safety tolerability rotigotine subject idiopathic Restless Legs Syndrome ( RLS ) , administer optimal dose 1 year subject previously participate SP790 ( 6-month pivotal trial ) SP794 ( sleep lab trial ) . Subjects successfully complete Maintenance Period Taper Period SP790 SP794 allow enroll trial .</brief_summary>
	<brief_title>Phase 3 Open-label Extension Trial With Rotigotine Idiopathic Restless Legs Syndrome Subjects</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject complete Maintenance Period Taper Period SP790 SP794 Subject ongoing serious adverse event ( SAE ) SP790 SP794 assess related trial medication investigator and/or sponsor . Subject medical psychiatric condition , opinion investigator , jeopardize would compromise subject 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>